Join the Dementia group to help and get support from people like you.
Dementia News (Page 19)
Related terms: Chronic Brain Syndrome, DLB, Memory Loss
Could an App Help Predict Thinking Declines for Those With Alzheimer's?
THURSDAY, July 11, 2024 – Dutch researchers are developing an app to predict how individual cases of Alzheimer's disease will progress. Based on data from nearly 1,000 Alzheimer's patients, they...
New Research Points Towards Potential Treatment for Anorexia
THURSDAY, July 11, 2024 – Anorexia nervosa could be caused by lack of a specific brain chemical, reports a research team that has developed a possible cure for the eating disorder. Mouse studies...
In-Office Test Can Predict Likelihood of Seniors Passing On-Road Driving Test
FRIDAY, July 5, 2024 – A new in-office test (Fit2Drive) can predict an older individual's probability of passing an on-road driving test, according to a study published online June 3 in JAMDA, the...
FDA Approves Adlarity (donepezil transdermal system) for Treatment of Patients with Alzheimer’s Disease
BOSTON, March 14, 2022 /PRNewswire/ – Corium, Inc., a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies,...
FDA Approves Neuraceq (florbetaben F18 injection) for PET Imaging of Beta-Amyloid Plaques
Berlin/Boston, March 20, 2014‒ Piramal Imaging today announced that the U.S. Food and Drug Administration (FDA) has approved Neuraceq. This approval comes only four weeks after receiving marketing a...
Novartis Exelon Patch Now FDA Approved to Treat Patients Across all Stages of Alzheimer's Disease
EAST HANOVER, N.J., June 27, 2013 /PRNewswire/ – The US Food and Drug Administration (FDA) has expanded the approved indication for Exelon Patch (rivastigmine transdermal system) to include the...
Higher Dose of Novartis Drug Exelon Patch Approved By FDA for Patients With Mild to Moderate Alzheimer's Disease
EAST HANOVER, N.J., Sept. 4, 2012 /PRNewswire/ – The US Food and Drug Administration has approved a higher dose of Exelon Patch (rivastigmine transdermal system) for the treatment of people with...
FDA Approves Amyvid (Florbetapir F 18 Injection) for Use in Patients Being Evaluated for Alzheimer's Disease and Other Causes of Cognitive Decline
INDIANAPOLIS, April 6, 2012 /PRNewswire/ – Eli Lilly and Company and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, today announced the U.S. Food and Drug Administration (FDA)...
FDA Medwatch Alert: Antipsychotics, Conventional and Atypical
[Posted 06/16/2008] FDA notified healthcare professionals that both conventional and atypical antipsychotics are associated with an increased risk of mortality in elderly patients treated for...
FDA Medwatch Alert: Atypical Antipsychotic Drugs
The Food and Drug Administration has issued a public health advisory to alert health care providers, patients, and patient caregivers to new safety information concerning an unapproved, “off-label” us...